Brain Metastases From Non-small-cell Lung Cancer With EGFR Mutations Are Sensitive To Whole Brain Radiotherapy

Objective:Whole brain radiotherapy(WBRT) is the standard treatment method for brain metastases(BM).Previous studies have shown that Non-Small–Cell Lung Cancer(NSCLC) with Epidermal Growth Factor Receptor(EGFR) mutation is more sensitive to radiotherapy than EGFR wild type in vitro, while in vivo study the similar result has not been carried out yet. Herein, we investigated the association between WBRT efficacy and EGFR status of NSCLC BM patients Methods:A panel of 73 NSCLC patients with BM received the WBRT treatment. The standard regimen was 30 to 40 Gy in 10 to 20 fractions. The radiographic response rate(RR) in BM after WBRT, intracranial progression-free survival(IPFS) and overall survival(OS) were analyzed.Results:The overall median survival time was 11.1 months(95%CI 7.980-14.220).The total RR was 55%. Moreover, the ECOG PS at BM, control of primary tumor and EGFR mutation status were significantly associated with higher RR(p=0.051, 0.022 and 0.033,respectively). ECOG PS at BM, control of primary tumor and EGFR mutation were the significant prognostic factors for IPFS(p=0.004, 0.012 and 0.038, respectively).While,for OS, ECOG PS at BM, control of primary tumor and gender were the significant prognostic factors(p=0.002, 0.008 and 0.031, respectively).Conclusions:EGFR mutation is significantly associated with better response to WBRT in NSCLC patients with BM.